Cost Effectiveness of Memantine in Moderately Severe to Severe Alzheimer’s Disease: A Markov Model in Finland

Author： François C.  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.24, Iss.7, 2004-01, pp. : 373-384

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Systematic Review of the Clinical and Cost-Effectiveness of Memantine in Patients with Moderately Severe to Severe Alzheimer's Disease

By Kirby Joanna   Green Colin   Loveman Emma   Clegg Andrew   Picot Joanna   Takeda Andrea   Payne Elizabeth  

Drugs & Aging, Vol. 23, Iss. 3, 2006-01 ,pp. : 227-240

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Memantine in Alzheimer’s Disease: An Analysis Based on a Probabilistic Markov Model from a UK Perspective

By Roy W. Jones  

Drugs & Aging, Vol. 21, Iss. 9, 2004-01 ,pp. : 607-620

Adis International

Access to resources Recommend Favorite

Memantine in Moderately-Severe-to-Severe Alzheimer's Disease: A Postmarketing Surveillance Study

By Clerici Francesca  

Drugs & Aging, Vol. 26, Iss. 4, 2009-05 ,pp. : 321-332

Adis International

Access to resources Recommend Favorite

Memantine cost saving in moderately-severe to severe AD

By  

Inpharma, Vol. 1, Iss. 1450, 2004-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer’s disease?

By Doggrell Sheila  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 10, 2003-10 ,pp. : 1857-1860

Informa Healthcare

Access to resources Recommend Favorite